Q-omics provides the consensus-scored HIF3A profile across patient tissues and cancer cell-line models. HIF3A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HIF3A is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, HIF3A RNA expression shows 15,793 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, BLCA, and THYM as cancer lineages where HIF3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIF3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIF3A survival associations across molecular data types. HIF3A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (13) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIF3A RNA expression–survival associations across cancer types. High HIF3A expression shows unfavorable associations in UCEC, OV and THCA, but favorable associations in UCS, HNSC and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for HIF3A RNA expression.
This table summarizes HIF3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HIF3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIF3A shows lower tumor expression in BLCA, COAD, THCA, LUSC, BRCA and LUAD. The BLCA box plot shows higher HIF3A RNA expression in normal versus tumor tissue (log2 FC = −4.175, t-test p < 0.001).
This table shows molecular features associated with HIF3A in patient tissues and cancer cell lines. In patient samples, HIF3A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HIF3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
